Evidence map›Paper›PMID 34124346›Full record

ArticleTransplantation direct2021

Causes and Circumstances of Death in Portopulmonary Hypertension.

Sandeep Sahay, Sami Al Abdi, Celia Melillo, Jennie Newman, Raed A Dweik, Gustavo A Heresi, Adriano R Tonelli

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation direct, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. International Liver Transplantation Society practice guideline update on portopulmonary hypertension.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2026
    Guideline
  2. Article
  3. Review
  4. Article
  5. Article
  6. Treatment pattern and clinical outcomes in portopulmonary hypertension: A database study in Japan.JGH open : an open access journal of gastroenterology and hepatology · 2022
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sandeep SahayWeill Cornell Medical College, Institute of Academic Medicine, Houston Methodist Lung Center, Houston Methodist Hospital, Houston, TX.
Sami Al AbdiInflammation and Immunity Department, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.
Celia MelilloInflammation and Immunity Department, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.
Jennie NewmanInflammation and Immunity Department, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.
Raed A DweikInflammation and Immunity Department, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.
Gustavo A HeresiInflammation and Immunity Department, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.
Adriano R TonelliInflammation and Immunity Department, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.
Cleveland Clinic · US

Funding

Extrapulmonary Microvascular Dysfunction in Pulmonary Arterial HypertensionR01HL130307 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI TONELLI, ADRIANO · 2016 to 2020
$2.0M
NHLBI NIH HHS R01 HL130307
6 · The paper itself

Abstract

The causes and circumstances surrounding death are poorly studied in patients with portopulmonary hypertension (PoPH). We sought to determine the specific reasons for dying and characteristics surrounding this process in patients with PoPH.

methodsAll deaths of patients with PoPH followed in the Cleveland Clinic Pulmonary Vascular Program were prospectively reviewed by the pulmonary hypertension team between 1996 and 2020.

resultsA total of 69 patients with PoPH (age 56.0 ± 8.9 y), with 49% females, were included. Causes of death were available in 52 (75%) patients, of these PoPH either directly or indirectly contributed to death in 13 of 52 (25%) of patients, meanwhile 39 of 52 (75%) of the patients died because of progressive liver disease and its related complications. Decompensated liver disease was the leading cause of death in this cohort 20 of 52 (38%), whereas 19 of 52 (37%) died because of conditions associated with liver disease. About half, 36 of 69 (52%) of patients died in a healthcare environment and 23 of 36 (64%) during a hospitalization at Cleveland Clinic. A total of 59 of 69 (74%) of patients received pulmonary arterial hypertension (PAH)-specific therapies. Six patients died after liver transplantation (in 3 death was related to PAH-related complications). Most of the patients in this cohort of PoPH patients were considered unsuitable for liver transplantation for a variety of reasons. Advanced healthcare directives were available in only 28% of patients.

conclusionsMost patients with PoPH died because of complications of their liver disease. PAH directly or indirectly contributed to death in a third of them. A quarter of them did not receive PAH-specific therapy before their death.

Identifiers

PMID34124346
PMCPMC8191691
OpenAlexW3169091295

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.